Related posters
(Anaveon) ANV600 is a novel PD-1 targeted IL-2Rβ/γ agonist that is combinable with therapeutic PD-1 inhibitors
Novel PD-1 targeted IL-2Rβ/γ agonist
November 1, 2023
Background
ANV600 combines a unique non-blocking PD-1 targeting approach with an IL-2Rβ/γ selective agonistic principle
The first arm of the bispecific antibody features an αIL-2/IL-2 fusion protein, which effectively prevents IL-2Rα from binding to the cytokine and therefore selectively activates IL-2Rβ/γ.The second arm consists of a high affinity αPD-1antibody to selectively deliver the IL-2Rβ/γ agonist to tumor antigen experienced PD-1+ T cells. The αPD-1arm binds to a unique epitope on PD-1 that enables combination of ANV600 with PD-1 checkpoint inhibitors.
Ultimate predictive models
Physiological relevance
Comprehensive and reliable validation data
Over 600 scientific articles based on our models
Scientific excellence
In-depth expertise in preclinical science, physiology, and model development
Unique R&D platform located in France
Customer-centric
Tailor-made approach to your needs
Strong emphasis on customer satisfaction
Collaborative partner
Long-standing partnerships with 17 of the top 20 pharma companies
Co-development of innovative models for next-generation drugs
Guaranteed FTO/freedom to operate